Impact of Early Cyclosporine on Cytokine Release Syndrome and Outcomes in Pediatric Haploidentical Hematopoietic Stem Cell Transplantation
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Veerendra C Patil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Pediatric Haematology Oncology, Basavatarakam Indo-American Cancer hospital and Research Institute, Hyderabad, India. Hauptthemen laut MEDLINE: Cyclosporine, Immunosuppressive Agents, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
Cytokine release syndrome (CRS) is a frequent early complication of T cell–replete peripheral blood haploidentical hematopoietic stem cell transplantation (PB‐haploHSCT), particularly in pediatric recipients. Post‐transplant cyclophosphamide (PTCy) is the standard for graft‐versus‐host disease (GVHD) prophylaxis, but the role of early cyclosporine initiation in this setting remains underexplored.
Methods
We retrospectively analyzed 50 pediatric patients with hematolymphoid malignancies who underwent PB‐haploHSCT with uniform myeloablative conditioning between 2017 and 2024. GVHD prophylaxis included PTCy and cyclosporine initiated on Day −2. CRS was graded according to ASTCT criteria. Survival and relapse outcomes were estimated using Kaplan–Meier and competing risk analyses.
Results
At a median follow‐up of 28 months, 68% of patients developed only Grade I CRS, with no cases of Grade ≥ II. The 2‐year overall survival (OS), relapse‐free survival (RFS), and GVHD‐free, relapse‐free survival (GRFS) were 72.1%, 65.5%, and 55.4%, respectively. The 2‐year transplant‐related mortality (TRM) was 6.0%. The cumulative incidence of grade III–IV acute GVHD was 14.1%, while moderate‐to‐severe chronic GVHD occurred in 6.8%. Although CRS was not associated with inferior survival, it was linked to a lower relapse incidence.
Conclusion
Early cyclosporine initiation before PTCy in pediatric PB‐haploHSCT appears feasible and may attenuate CRS without increasing GVHD or relapse risk. These findings support further prospective studies to validate early calcineurin inhibitor strategies in pediatric transplant protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Pediatric Haematology Oncology, Basavatarakam Indo-American Cancer hospital and Research Institute, Hyderabad, India.
- Department of Medical Oncology, Basavatarakam Indo-American Cancer hospital and Research Institute, Hyderabad, India.
Zitieren
APA
Patil, V. C., Dodda, S. R., Boyella, P. K., Tewani, R. K., Ladda, P. J., Somayajula, A. A., Krishnamohan, M. V. T., Sompalli, S., Koneru, S. H., & Rajappa, S. J. (2025). Impact of Early Cyclosporine on Cytokine Release Syndrome and Outcomes in Pediatric Haploidentical Hematopoietic Stem Cell Transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.70220
Vancouver
Patil VC, Dodda SR, Boyella PK, Tewani RK, Ladda PJ, Somayajula AA, et al. Impact of Early Cyclosporine on Cytokine Release Syndrome and Outcomes in Pediatric Haploidentical Hematopoietic Stem Cell Transplantation. Pediatric Transplantation. 2025. doi:10.1111/petr.70220
BibTeX
@article{Patil2025,
author = {Patil, Veerendra C and Dodda, Siddhartha Reddy and Boyella, Pavan Kumar and Tewani, Rohan Kamlesh and Ladda, Pallavi J and Somayajula, Anjana Alekhya and Krishnamohan, M V T and Sompalli, Sreeramakrishnaiah and Koneru, Shree Hasitha and Rajappa, Senthil J},
title = {Impact of Early Cyclosporine on Cytokine Release Syndrome and Outcomes in Pediatric Haploidentical Hematopoietic Stem Cell Transplantation},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70220}
}
EUVIMED